Recent Finacing
Recent Raise
Ottimo Pharma develops bifunctional PD‑1/VEGFR2 antibody therapeutics, advancing lead candidate Jankistomig (IV and SC), conducting IND‑enabling studies and preparing an IND dossier for late‑2025 clinical entry.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Ottimo Pharma.
